Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan for Prevention of Cancer Therapy-Related Cardiac Dysfunction
NCT05892146Phase 2Recruiting
- Sponsor
- National Cheng Kung University Hospital
- Start
- May 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacubitril + valsartan in Cardiotoxicity, sponsored by National Cheng Kung University Hospital. Started May 2021; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT05892146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892146.